United Therapeutics (UTHR) Misses Q2 EPS, Revenues Beat
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $514.32 +0.77%
EPS Growth %: -10.1%
Financial Fact:
Basic (in shares): 43.2M
Today's EPS Names:
PMCB, PLCE, DOMO, More
EPS Growth %: -10.1%
Financial Fact:
Basic (in shares): 43.2M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $2.41, $1.97 worse than the analyst estimate of $4.38. Revenue for the quarter came in at $466.9 million versus the consensus estimate of $460.67 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Yum! Brands completes Pizza Hut sale to LongRange for $1.5B
- Kustom Entertainment agrees to buy Tickets For Less operator TFL
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
